Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Equillium Inc

EQ
Current price
0.53 USD -0.048 USD (-8.19%)
Last closed 0.58 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 17 907 280 USD
Yield for 12 month -67.73 %
Week
Month
Year
EQ
21.11.2021 - 28.11.2021

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California. Address: 2223 Avenida De La Playa, La Jolla, CA, United States, 92037

Analytics

WallStreet Target Price

8 USD

P/E ratio

Dividend Yield

Current Year

+15 759 000 USD

Last Year

Current Quarter

+8 870 000 USD

Last Quarter

+9 124 000 USD

Current Year

+15 759 000 USD

Last Year

Current Quarter

+8 870 000 USD

Last Quarter

+9 124 000 USD

Key Figures EQ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -9 155 000 USD
Operating Margin TTM -40.85 %
PE Ratio
Return On Assets TTM -11.17 %
PEG Ratio
Return On Equity TTM -31.45 %
Wall Street Target Price 8 USD
Revenue TTM 42 632 000 USD
Book Value 0.69 USD
Revenue Per Share TTM 1.24 USD
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM 15 759 000 USD
Earnings Share -0.22 USD
Diluted Eps TTM -0.22 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -19.28 %

Dividend Analytics EQ

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History EQ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation EQ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.1214
Price Book MRQ 1.4883

Financials EQ

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators EQ

For 52 weeks

0.45 USD 1.75 USD
50 Day MA 0.62 USD
Shares Short Prior Month 498 670
200 Day MA 0.72 USD
Short Ratio 9.41
Shares Short 492 007
Short Percent 2.3 %